SmiLe Incubator

SmiLe Incubator is a business incubator located at Medicon Village in Lund, Sweden. They help entrepreneurs and early stage companies in the life sciences develop and commercialize new ideas.

Ebba Fåhraeus

CEO

Ulrika Ringdahl

CEO

21 past transactions

Yazen

Angel Round in 2022
Yazen is a digital healthcare provider focused on offering customized weight loss programs primarily for middle-aged men dealing with obesity and related health issues, including potential testosterone deficiencies. The platform connects users with a multidisciplinary team of professionals, such as doctors, psychologists, dietitians, and personal trainers, to develop personalized weight management plans. By analyzing individual data, Yazen provides recommendations for lifestyle changes and, when necessary, medication to enhance both physical and mental well-being.

Call Knut

Angel Round in 2022
Call Knut is the developer of communication software designed to check in the elderly.

Saveggy

Seed Round in 2022
Saveggy develops a bio-based edible vegan coating for fruit and vegetables eliminating plastic while keeping its protecting properties.

Manje Health

Venture Round in 2021
Manje Health is a search and discovery platform for chronic disease treatment.

Xaga Surgical

Venture Round in 2021
Xaga Surgical focuses on developing innovative medical needles designed to minimize the risk of infections associated with their use. The company's products aim to significantly reduce the risk of severe sepsis by virtually eliminating bacterial transfer during needle insertion. This advancement enhances safety not only in the diagnosis of prostate cancer but also in various other medical applications, ultimately helping patients lower their chances of developing severe infections.

TIGERQ

Seed Round in 2021
TIGERQ is a provider of gene editing analysis services focused on accelerating biomedical innovation. The company specializes in a sample-to-analysis solution that integrates proprietary sequencing algorithms with efficient and cost-effective sample processing. By leveraging the CRISPR-Cas9 gene editing method, TIGERQ aims to assist drug researchers in reducing the lead time required for developing new medicines and vaccines. Their offerings are designed to enhance the speed and efficacy of biomedical research, ultimately contributing to advancements in healthcare.

Syntaxis

Grant in 2018
Syntaxis is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.

In2cure

Venture Round in 2018
In2cure is a company that exploits new scientific discoveries on natural host defenses for novel therapies.

Thyrolytics

Seed Round in 2018
Thyrolytics specializes in the development of an innovative diagnostic device that measures serum levels of free T4 and T3, key thyroid hormones. Utilizing advanced nanotechnology and protein engineering, the company offers a reliable and cost-effective point-of-care solution for monitoring thyroid hormone levels in the blood. This technology aims to enhance the management of thyroid health, providing users with a straightforward method to ensure their thyroid function is maintained effectively.

ReceptorPharma

Seed Round in 2018
ReceptorPharma is a drug discovery company utilizing a completely new pathway to treat Alzheimer’s disease.

Bionamic

Seed Round in 2018
Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.

SAGA Diagnostics

Grant in 2017
SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Medow

Seed Round in 2017
Medow is a company focused on creating innovative healthcare products that enhance patient comfort and improve efficiency in medical settings. One of its key offerings is a reusable medical bracelet designed to securely hold intravenous tubes in place during treatments. This slap-on bracelet ensures that the intravenous needle remains stable throughout the procedure, significantly reducing the need for nurses to frequently reattach tape or insert new needles. By prioritizing design and functionality, Medow aims to make healthcare experiences more pleasant for patients while optimizing the workflow for healthcare professionals.

Medotemic

Seed Round in 2017
Medotemic AB, founded in 2016 and based in Lund, Sweden, specializes in developing innovative solutions for analyzing gait deviations, particularly those resulting from injuries or pain. The company's main product, Medomotion, is a mobile application that leverages smartphone sensor data to provide objective analysis of movement patterns during walking and running. By utilizing proprietary algorithms, Medotemic offers detailed insights into gait deviations, enabling users to measure and improve their movement through personalized training plans. The application also facilitates remote monitoring for both consumers and healthcare professionals, providing immediate feedback that can enhance treatment and recovery processes. Through its technology, Medotemic aims to increase awareness and motivate users to adhere to their rehabilitation programs.

POOW Applications

Seed Round in 2017
POOW Applications has developed The Food Hero app that helps children with different types of eating disorders.

Gedea Biotech

Seed Round in 2016
Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

Truly Labs

Seed Round in 2016
Truly Labs provides tailor-made in vitro and in vivo services.

Cellevate

Seed Round in 2015
Cellevate is an innovative biotech company that develops the next generation of cell culture systems.

MedVasc

Seed Round in 2014
MedVasc has developed Solution a patented medical device that reduces pain when treating varicose veins.

Speximo

Seed Round in 2013
Speximo AB, founded in 2012 and based in Lund, Sweden, specializes in developing starch-based emulsifiers derived from quinoa for surfactant-free emulsions. The company operates in the cosmetics, pharmaceutical, and food industries, providing sustainable solutions for the stabilization of oil-water-based products. Speximo’s patented technology allows for the encapsulation of active ingredients, ensuring stable formulations while enhancing the texture of end products. The company collaborates closely with researchers from Lund University and Malmö University to advance its understanding of starch Pickering emulsions and explore new applications. Since 2013, Speximo has been located in Medicon Village, where it focuses on solving formulation challenges and innovating environmentally friendly alternatives in product development. As of September 2019, Speximo operates as a subsidiary of Lucas Meyer Cosmetics Canada, Inc.

SARomics Biostructures

Venture Round in 2012
SARomics Biostructures AB, founded in 2006 and based in Lund, Sweden, provides a comprehensive range of structural biology and structure-based drug discovery services to biotech and pharmaceutical companies, as well as non-profit institutions globally. The company's offerings include crystallography and NMR spectroscopy services, encompassing protein crystallization, structure determination, and ligand binding assays. Additionally, SARomics specializes in gene-to-structure services that involve protein cloning, expression, purification, and structural analysis. Its expertise extends to kinase structures and fragment-based drug discovery, along with structure-based drug discovery services that facilitate hit identification and lead optimization. The company also provides computational chemistry and contract drug discovery services, focusing on optimizing protein structures and activities. By supplying essential insights into the interactions between drug substances and target molecules, SARomics aids in the efficient development of new pharmaceuticals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.